title: [Urethral recurrence after cysto-prostatectomy for bladder tumor].
abstract: OBJECTIVE
  To evaluate the frequency, predictive parameters and prognosis of urethral recurrence after cystoprostatectomy for urothelial bladder cancer.
  
  
  METHODS
  From 1989 to 1994, 8 of a series of 185 patients (4.3%) treated by cystoprostatectomy for bladder carcinoma between 1988 and 1993 developed urethral recurrence revealed by urethral bleeding, with a follow-up of 6 to 36 months (m = 16).
  
  
  RESULTS
  The initial bladder tumour was localized in 3 cases and multifocal in 5 cases. The posterior urethra was not involved in 5 cases, but presented lesions of CIS in 1 case and neoplastic infiltration also involving the prostate in 2 cases. These recurrences were treated by urethrectomy, as first-line treatment in 7 cases and after failure of endoscopic treatment in 1 case. A balanic recurrence required distal penectomy following insufficient urethral resection. The course was very rapidly unfavourable for 3 patients with generalized cancer and an intercurrent disease was fatal in 1 other case. With a follow-up of 12 to 44 months (m = 26), 4 patients are alive with no obvious signs of disease progression.
  
  
  CONCLUSIONS
  The indications for prophylactic urethrectomy can be reserved to patients with positive urethral resection margins, provided all other cases are submitted to strict surveillance. In the context of a replacement bladder, it is essential to exclude neoplastic involvement of the posterior urethra or prostate, especially in patients previously treated by intravesical instillations.
authors.affiliation: Service d'Urologie I, Hôpital Lapeyronie, Montpellier, France.
authors.forename: M
authors.initials: M
authors.lastname: Robert
authors.forename: J S
authors.initials: JS
authors.lastname: Burgel
authors.forename: I
authors.initials: I
authors.lastname: Serre
authors.forename: J
authors.initials: J
authors.lastname: Guiter
authors.forename: D
authors.initials: D
authors.lastname: Grasset
mesh_terms: D002277:Carcinoma / Q000473:pathology / Q000601:surgery*; D002278:Carcinoma in Situ / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery; D015653:Cystectomy; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology* / Q000601:surgery; D010412:Penile Neoplasms / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011468:Prostatectomy; D015996:Survival Rate; D014523:Urethral Neoplasms / Q000473:pathology* / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery*